Related Experiment Video
Updated: Jul 1, 2025
Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging
Published on: June 7, 2020
From pre-clinical to translational brain metastasis research: current challenges and emerging opportunities
Emilija Aleksandrovic1, Siyuan Zhang2, Dihua Yu3
1Department of Pathology, Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, 6001 Forest Park Rd, Dallas, TX, 75235, USA.
Abstract:
Brain metastasis, characterized by poor clinical outcomes, is a devastating disease. Despite significant mechanistic and therapeutic advances in recent years, pivotal improvements in clinical interventions have remained elusive. The heterogeneous nature of the primary tumor of origin, complications in drug delivery across the blood-brain barrier, and the distinct microenvironment collectively pose formidable clinical challenges in developing new treatments for patients with brain metastasis. Although current preclinical models have deepened our basic understanding of the disease, much of the existing research on brain metastasis has employed a reductionist approach. This approach, which often relies on either in vitro systems or in vivo injection models in young and treatment-naive mouse models, does not give sufficient consideration to the clinical context. Given the translational importance of brain metastasis research, we advocate for the design of preclinical experimental models that take into account these unique clinical challenges and align more closely with current clinical practices. We anticipate that aligning and simulating real-world patient conditions will facilitate the development of more translatable treatment regimens. This brief review outlines the most pressing clinical challenges, the current state of research in addressing them, and offers perspectives on innovative metastasis models and tools aimed at identifying novel strategies for more effective management of clinical brain metastasis.
Insights
Brain metastasis research needs better preclinical models that mimic patient conditions for improved treatments. Current models are too simplistic, hindering progress in this devastating disease.
Area of Science:
- Neuro-oncology
- Translational Cancer Research
- Clinical Metastasis Studies
Background:
- Brain metastasis presents significant clinical challenges due to tumor heterogeneity, drug delivery issues across the blood-brain barrier, and a unique microenvironment.
- Despite advances, pivotal improvements in clinical interventions for brain metastasis have been limited.
- Current preclinical models often use reductionist approaches (in vitro, young/treatment-naive in vivo models) that lack clinical relevance.
Purpose of the Study:
- To highlight the critical need for preclinical models that better simulate the clinical complexities of brain metastasis.
- To review current research challenges and perspectives on innovative metastasis models and tools.
- To advocate for the development of more translatable preclinical strategies for brain metastasis.
Main Methods:
- Review of existing literature on brain metastasis mechanisms, preclinical models, and clinical challenges.
- Analysis of the limitations of current reductionist preclinical approaches.
- Discussion of innovative models and tools for future brain metastasis research.
Main Results:
- Current preclinical models inadequately represent the clinical reality of brain metastasis.
- Significant challenges in brain metastasis treatment stem from primary tumor heterogeneity, blood-brain barrier penetration, and the tumor microenvironment.
- There is a clear need for advanced, clinically relevant preclinical models.
Conclusions:
- Developing preclinical models that align with clinical realities is crucial for advancing brain metastasis treatment.
- Innovative models and tools are needed to overcome existing translational gaps.
- Improved preclinical strategies will facilitate the development of more effective therapeutic regimens for patients with brain metastasis.
